20 Years Of Biosimilars: Are We On The Right Track?

The biosimilar industry has seen remarkable growth over the past two decades, with the global market valued at USD 35 billion in 2022 and projected to more than double by 2030. Biosimilars offer the promise of comparable treatments at lower costs, making healthcare more accessible. However, the journey has not been without challenges, including regulatory hurdles and stakeholder acceptance.

This white paper captures insights from a recent PharmaLex panel discussion on the evolving landscape of biosimilars. In this discussion, industry experts delve into regulatory challenges, market acceptance, and the future of biosimilars in expanding patient access to therapies for cancer, autoimmune diseases, and diabetes. Led by Dr. Christian K Schneider, the panel highlights the progress and ongoing barriers in biosimilar development, emphasizing the need for continued innovation and collaboration.  This discussion underscores the importance of industry-regulator collaboration and scientific flexibility to sustain the momentum of biosimilar development and integration into new therapeutic areas.

Key learning objectives:

• The current state of the biosimilars market
• Shifts in stakeholder acceptance
• Market opportunities by originator companies
• Challenges and barriers that remain
• Experts’ predications on what’s to come